Novel approaches for the treatment of small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 2, 2004, Pages 499-518

  Wakelee, Heather ^a   Kelly, Karen ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BB 1 0901; BORTEZOMIB; CARBOPLATIN; CGP 69846A; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; IMATINIB; MARIMASTAT; OBLIMERSEN; PACLITAXEL; POLYSIALIC ACID; RETINOIC ACID; SULINDAC SULFONE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANASARCA; ANEMIA; ANGIOGENESIS; BONE MARROW SUPPRESSION; CELL SURVIVAL; CLINICAL TRIAL; CONFUSION; DIARRHEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CELL SURVIVAL; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 1942503367     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.01.001     Document Type: Review

References (86)

1. Wistuba I.I., Gazdar A.F., Minna J.D. Molecular genetics of small cell lung carcinoma. Semin Oncol. 28(2):2001;3-13.
2. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part I. J Clin Oncol. 20(12):2002;2881-2894.
3. Richardson G.E., Johnson B.E. The biology of lung cancer. Semin Oncol. 20(2):1993;105-127.
4. Matsuda R., Takahashi T., Nakamura S., Sekido Y., Nishida K., Seto M.et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol. 142(1):1993;339-346.
5. Arber D.A., Tamayo R., Weiss L.M. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 29(5):1998;498-504.
6. TM) for patients with small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 21:2002;293a. Abstract 1171.
7. Micke P., Basrai M., Faldum A., Bittinger F., Ronnstrand L., Blaukat A.et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 9(1):2003;188-194.
8. Blackhall F.H., Pintilie M., Michael M., Leighl N., Feld R., Tsao M.S.et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 9(6):2003;2241-2247.
9. Prins J., DeVries E.G., Mulder N.H. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 13(5A):1993;1373-1385.
10. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. J Clin Oncol. 16(3):1998;1207-1217.
11. Zereu M., Vinholes J., Zettler C. p53 and bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung Cancer. 4(5):2003;298-302.
12. Maitra A., Amirkhan R.H., Saboorian M.H., Frawley W.H., Ashfaq R. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol. 30(6):1999;712-717.
13. Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res. 15(2):1995;503-505.
14. Jiang S.X., Sato Y., Kuwao S., Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 177(2):1995;135-138.
15. Kaiser U., Schilli M., Haag U., Neumann K., Kreipe H., Kogan E.et al. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer. 15(1):1996;31-40.
16. Sekido Y., Fong K.M., Minna J.D. Molecular biology of lung cancer. deVita V.T., Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. 6th edition:2001;917-924 Lippincott Williams & Wilkins, Philadelphia.
17. Rodriguez-Salas N., Palacios J., Moreno G., de Castro J., Gonzalez-Baron M., Gamallo C. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer. 34(1):2001;67-74.
18. Harbour J.W., Lai S.L., Whang-Peng J., Gazdar A.F., Minna J.D., Kaye F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 241(4863):1988;353-357.
19. Cagle P.T., el-Naggar A.K., Xu H.J., Hu S.X., Benedict W.F. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am J Pathol. 150(2):1997;393-400.
20. Zhang S., Cordon-Cardo C., Zhang H.S., Reuter V.E., Adluri S., Hamilton W.B.et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer. 73(1):1997;42-49.
21. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part II. J Clin Oncol. 20(13):2002;3016-3028.
22. Lucchi M., Mussi A., Fontanini G., Faviana P., Ribechini A., Angeletti C.A. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg. 21(6):2002;1105-1110.
23. Mall J.W., Schwenk W., Philipp A.W., Meyer-Kipker C., Mall W., Muller J.et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology. 7(2):2002;99-102.
24. Michael M., Babic B., Khokha R., Tsao M., Ho J., Pintilie M.et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 17(6):1999;1802-1808.
25. Heasley L.E., Johnson G.L. Signal transduction abnormalities in lung cancer. Kane M.A., Bunn P.A. Jr. Biology of lung cancer. 1998;371-390 Marcel Dekker, New York.
26. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A.et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 316(6031):1985;823-826.
27. Chaudhry A., Carrasquillo J.A., Avis I.L., Shuke N., Reynolds J.C., Bartholomew R.et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 5(11):1999;3385-3393.
28. Kelley M.J., Linnoila R.I., Avis I.L., Georgiadis M.S., Cuttitta F., Mulshine J.L.et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 112(1):1997;256-261.
29. Marquez C., Treston A., Moody E., Jakowlew S., Moody T.W. The metabolism of BW2258U89, a GRP receptor antagonist. Neuropeptides. 34(2):2000;108-115.
30. Jones D.A., Cummings J., Langdon S.P., Smyth J.F. Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Gen Pharmacol. 28(2):1997;183-189.
31. Clive S., Webb D.J., MacLellan A., Young A., Byrne B., Robson L.et al. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res. 7(10):2001;3071-3078.
32. Chan D.C., Gera L., Stewart J.M., Helfrich B., Zhao T.L., Feng W.Y.et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 8(5):2002;1280-1287.
33. MacKinnon A.C., Waters C., Jodrell D., Haslett C., Sethi T. Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem. 276(30):2001;28083- 28091.
34. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 6(8):2000;3319-3326.
35. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 20(6):2002;1692-1703.
36. Heymach J., DePorre P., DeVore R., Johnson D., Khuri F.R., Richards H. Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 21:2002;319a. Abstract 1275.
37. Rudin C.M., Holmlund J., Fleming G.F., Mani S., Stadler W.M., Schumm P.et al. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 7(5):2001;1214-1220.
38. Brennan J., O'Connor T., Makuch R.W., Simmons A.M., Russell E., Linnoila R.I.et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res. 51(6):1991;1708-1712.
39. Kalemkerian G.P., Jasti R.K., Celano P., Nelkin B.D., Mabry M. All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung cancer. Cell Growth Differ. 5(1):1994;55-60.
40. Kalemkerian G.P., Jiroutek M., Ettinger D.S., Dorighi J.A., Johnson D.H., Mabry M. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer. 83(6):1998;1102-1108.
41. Ohlmann C.H., Jung C., Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl) retinamide] sufficient for cancer therapy? Int J Cancer. 100(5):2002;520-526.
42. Sartorius U.A., Krammer P.H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 97(5):2002;584-592.
43. Ziegler A., Luedke G., Fabbro D., Altmann K.-H., Stahel R., Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting bcl-2 coding sequence. J Natl Cancer Inst. 89(14):1997;1027-1036.
44. Zangemeister-Wittke U., Schenker T., Luedke G., Stahel R. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer lines. Br J Cancer. 78:1998;1035-1042.
45. Rudin C.M., Otterson G.A., Mauer A.M., Villalona-Calero M.A., Tomek R., Prange B.et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 13(4):2002;539-545.
46. Rudin C., Kozloff M., Edelman M., Hoffman P., Szeto L., Vokes E.E. Phase I study of G3139 (oblimersen sodium), carboplatin and etoposide in previously untreated extensive stage small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 22:2003;631. Abstract 2538.
47. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L.et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57(12):1997;2452-2459.
48. Thompson W.J., Piazza G.A., Li H., Liu L., Fetter J., Zhu B.et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 60(13):2000;3338-3342.
49. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn P.A. Jr., Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 59(24):1999;6178-6184.
50. Duffy C., Elliott C., O'Connor R. Enhancement of chemotherapy drug toxicity to human tumor cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAID). Eur J of Oncology. 34:1998;1250-1259.
51. Campling B., Young L., Baer K. Expression of the MRP and MDR multidrug resistance gene in small cell lung cancer. Clin Cancer Res. 3:1997;115-122.
52. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D.et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59(11):1999;2615-2622.
53. Cusack J.C. Jr., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J.et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61(9):2001;3535-3540.
54. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J.et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 8(8):2002;2505-2511.
55. Raymond E., Alexandre J., Depenbrock H., Mekhaldi S., Angevin E., Hanauske A. CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule [abstract]. Proc Am Soc Clin Oncol. 19:2000;187a. Abstract 728.
56. Hidalgo M., Rowinsky E., Erlichman C., Drengler R., Marshall B., Adjei A. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study [abstract]. Proc Am Soc Clin Oncol. 19:2000;187a. Abstract 726.
57. Mattson K., Niiranen A., Ruotsalainen T., Maasilta P., Halme M., Pyrhonen S.et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. J Interferon Cytokine Res. 17(2):1997;103-105.
58. Kelly K., Crowley J.J., Bunn P.A. Jr., Hazuka M.B., Beasley K., Upchurch C.et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 13(12):1995;2924-2930.
59. Ruotsalainen T., Halme M., Isokangas O.P., Pyrhonen S., Mantyla M., Pekonen M.et al. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer - a feasibility study. Anticancer Drugs. 11(2):2000;101-108.
60. Jett J.R., Maksymiuk A.W., Su J.Q., Mailliard J.A., Krook J.E., Tschetter L.K.et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol. 12(11):1994;2321-2326.
61. van Zandwijk N., Groen H.J., Postmus P.E., Burghouts J.T., ten Velde G.P., Ardizzoni A.et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 33(11):1997;1759-1766.
62. Zarogoulidis K., Ziogas E., Papagiannis A., Charitopoulos K., Dimitriadis K., Economides D.et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. Lung Cancer. 15(2):1996;197-205.
63. Prior C., Oroszy S., Oberaigner W., Schenk E., Kummer F., Aigner K.et al. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J. 10(2):1997;392-396.
64. Khuri F.R., Fossella F.V., Lee J.S., Murphy W.K., Shin D.M., Markowitz A.B.et al. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res. 18(4):1998;241-245.
65. DiPaola R.S., Rafi M.M., Vyas V., Toppmeyer D., Rubin E., Patel J.et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol. 17(7):1999;2213-2218.
66. Winter S.F., Sekido Y., Minna J.D., McIntire D., Johnson B.E., Gazdar A.F.et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst. 85(24):1993;2012-2018.
67. Chapman P.B., Houghton A.N. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest. 88(1):1991;186-192.
68. Grant S.C., Kris M.G., Houghton A.N., Chapman P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res. 5(6):1999;1319-1323.
69. Cappello S., Liu N.X., Musselli C., Brezicka F.T., Livingston P.O., Ragupathi G. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells. Cancer Immunol Immunother. 48(9):1999;483-492.
70. Dickler M.N., Ragupathi G., Liu N.X., Musselli C., Martino D.J., Miller V.A.et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res. 5(10):1999;2773-2779.
71. Krug L., Ragupathi G., Livingston P., Tyson L., Hood C., Baez V. Pilot trial of a synthetic fucosyl-GM1 ganglioside vaccine in patients with small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 21:2002;4b. Abstract 1824.
72. Ng K., Kris M., Miller V., Krug L., Michaelson N., Livingston P. Vaccination with polysialic acid (polySA)-KLH or N-Propionylated (NP) polysialic acid-keyhole limpet hemocyanin (KLH) conjugate plus QS-21 in patients with small cell lung cancer (SCLC) after a major response to therapy [abstract]. Proc Am Soc Clin Oncol. 20:2001;223b. Abstract 2644.
73. Assersohn L., Souberbielle B.E., O'Brien M.E., Archer C.D., Mendes R., Bass R.et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol). 14(1):2002;23-27.
74. Koros A.M., Goodwin D.G., Siderits R.H., Malavasi F. "Natural killer" (NK) cell antigens CD56, CD57 and others are expressed on breast and lung tumor cells as well as sea urchin coelomocytes. J Biol Regul Homeost Agents. 16(3):2002;173-175.
75. Fossella F., Tolcher A., Elliott M., Lamber J., Lu R., Zinner R. Phase I trial of monoclonal antibody conjugates, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors [abstract]. Proc Am Soc Clin Oncol. 21:2002;309a. Abstract 1232.
76. Fontanini G., Faviana P., Lucchi M., Boldrini L., Mussi A., Camacci T.et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer. 86(4):2002;558-563.
77. Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 79(2):1998;144-146.
78. Dowell J., Amirkhan R., Lai W., Minna J. Survival in small cell lung cancer (SCLC) is independent of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) expression [abstract]. Proc Am Soc Clin Oncol. 22:2003;632. Abstract 2541.
79. Wedge S., Ogilvie D., Dukes M., Kendrew J., Henneqiun L., Stokes E. VEGF receptor tyrosine kinase inhibitors as potential anti-tumor targets [abstract]. Proc Am Assoc Cancer Res. 41:2000;566-567. Abstract 3610.
80. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 18(5):2000;1135-1149.
81. Shepherd F.A., Giaccone G., Seymour L., Debruyne C., Bezjak A., Hirsh V.et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 20(22):2002;4434-4439.
82. Shepherd F.A., Sridhar S. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer. 41:2003;S63-S72.
83. Rigas J., Denham C., Rinaldi D., Moore T., Smith J., Winston R. Randomized placebo-controlled trial of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 22:2003;628. Abstract 2525.
84. Lee S., James L., Mohamed-Ali V., Boschoff C., Snee M., Brock C. A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol. 21:2002;313a. Abstract 1251.
85. Peters K.B., Brown J.M. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 62(18):2002;5248-5253.
86. Le Q.-T., Chansky K., Williamson S., Edelman M., Ryu J., Gaspar L. SWOG 0004-pilot study of tirapazamine (TPZ) plus cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (RT) in limited small cell lung cancer (LSCLC) [abstract]. Proc Am Soc Clin Oncol. 21:2002;294a. Abstract 1174.